ArticleArthritis research & therapy2023
Alterations in lipidome profiles distinguish early-onset hyperuricemia, gout, and the effect of urate-lowering treatment.
Article in Arthritis research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of urate-lowering therapies in asymptomatic hyperuricaemia: a systematic review and network meta-analysis of key clinical outcomes.Annals of medicine · 2025Pooled it
- Gut microbiota and uric acid excretion signaling in pathogenesis of hyperuricemia and acute gouty arthritis.iScience · 2026Article
- Valproic acid remodels phosphatidylglycerol homeostasis and epithelial-macrophage crosstalk in inflammatory signaling.iScience · 2026Article
- Association between remnant cholesterol level and gout in US adults.The Journal of international medical research · 2026Article
- Aromatase Inhibitor Therapy Is Associated with Distinct Plasma Lipidomic Profiles in Postmenopausal Breast Cancer Patients.International journal of molecular sciences · 2026Article
- Article
- AdaBoost-based differential diagnosis of gouty arthritis and rheumatoid arthritis: model construction, temporal validation, and SHAP visualization.Frontiers in medicine · 2026Article
- Genetic and epigenetic contribution of ABCG2 to gout susceptibility: a case-control study.Molecular biology reports · 2025Article
- U- and inverted U-shaped link between weight-adjusted waist index and chronic kidney disease in hyperuricemic adults.BMC public health · 2025Article
- Hyperuricemia Is Independently Associated With Hyperlipidemia in a Large Population-Based Study.Journal of clinical laboratory analysis · 2025Article
- Incidence and prevalence of gout in Eastern China from 2011 to 2021: a retrospective population-based study.Annals of medicine · 2025Article
- Association of Hyperuricemia with Cardiovascular Risk Factors and Cardiac Structural Changes in Patients Undergoing Maintenance Hemodialysis in Southwest China.Medical science monitor : international medical journal of experimental and clinical research · 2025Article
- Best practices and tools in R and Python for statistical processing and visualization of lipidomics and metabolomics data.Nature communications · 2025Review
- Exercise effects on the link between inflammation, metabolic health and hyperuricemia: a prospective cohort study.Lipids in health and disease · 2025Article
- From plateau to plains: unraveling the diet-exercise paradox in uric acid homeostasis through a comprehensive comparative study.Clinical rheumatology · 2025Article
- Identification of pathogenic variants in the ABCG2 gene in patients with severe familial hyperuricemia and gout.Molecular and cellular biochemistry · 2025Article
- Article
- Metabolomic profiles underlying gout flares: a prospective study of people with gout.RMD open · 2025Article
- Association between lipid accumulation product (LAP) index and self-reported oral health outcomes: a cross-sectional study.Lipids in health and disease · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCurrently, it is not possible to predict whether patients with hyperuricemia (HUA) will develop gout and how this progression may be affected by urate-lowering treatment (ULT). Our study aimed to evaluate differences in plasma lipidome between patients with asymptomatic HUA detected ≤ 40 years (HUA ≤ 40) and > 40 years, gout patients with disease onset ≤ 40 years (Gout ≤ 40) and > 40 years, and normouricemic healthy controls (HC).
methodsPlasma samples were collected from 94 asymptomatic HUA (77% HUA ≤ 40) subjects, 196 gout patients (59% Gout ≤ 40), and 53 HC. A comprehensive targeted lipidomic analysis was performed to semi-quantify 608 lipids in plasma. Univariate and multivariate statistics and advanced visualizations were applied.
resultsBoth HUA and gout patients showed alterations in lipid profiles with the most significant upregulation of phosphatidylethanolamines and downregulation of lysophosphatidylcholine plasmalogens/plasmanyls. More profound changes were observed in HUA ≤ 40 and Gout ≤ 40 without ULT. Multivariate statistics differentiated HUA ≤ 40 and Gout ≤ 40 groups from HC with an overall accuracy of > 95%.
conclusionAlterations in the lipidome of HUA and Gout patients show a significant impact on lipid metabolism. The most significant glycerophospholipid dysregulation was found in HUA ≤ 40 and Gout ≤ 40 patients, together with a correction of this imbalance with ULT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.